| |
REAGENTS/MATERIAL:
Antibodies used in this study include: Rabbit anti-NEP (Chemicon, Temecula, CA, USA),
anti-IDE (Abcam, Cambridge, MA, USA),
goat anti-ECE-1 (R&D Systems, Minneapolis, MN, USA),
synaptophysin monoclonal antibody, a generous gift from Dr William Honer, University of British Columbia, Vancouver, Canada,
anti-β-Actin (Amersham, Piscataway, NJ, USA) and and anti-α-actin (Sigma-Aldrich, St Louis, MO, USA).
Sodium dodecyl sulfate–page acrylamide gel electrophoresis,
western blot and protein quantification:
mouse anti-Ab (Clone Ab9, a gift from Dr T. Golde, Mayo Clinic, Jacksonville, FL, USA),
rabbit anti-NEP antibody (Chemicon, Temecula, CA, USA),
mouse anti-IDE (Abcam, Cambridge, USA),
goat anti-ECE-1 (R&D Systems),
mouse anti-synaptophysin (EP10),
mouse monoclonal antibody BAN50 (recognizing the amino terminus of Ab),
mouse anti-b-actin (Amersham, Piscataway, NJ, USA)
or rabbit anti-a-actin antibodies (Sigma-Aldrich).
Insulin-degrading enzyme-specific activity: ELISA plates were coated with capture IDE antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
|